Skip to content

Basket

You currently have no items in your basket.

Total (excl. vat) £0.00
View basket & checkout
Proteins and Peptides

Tau dGAE (297-391) AD-mimic Pre-formed Fibrils

Product Sizes
100 ug
SPR-502-100UG
2 x 100 ug
SPR-502-2X100UG
500 ug
SPR-502-500UG
About this Product
SKU:
SPR-502
Additional Names:
Tau dGAE, Tau 297-391, Truncated Tau, Tau fragment 297-391, microtubule-associated tau, MAPT, MAP, Tau-441, Paired Helical Filament-Tau, Phf-Tau, Neurofibrillary Tangle, G Protein Beta1/Gamma2 Subunit-Interacting Factor 1, Isoform 2, tubulin-associated unit, Tau PFFs
Application:
Cell-based/Functional Assay, Western Blot
Buffer:
10mM PB pH 7.4, 10mM DTT, 200mM MgCl2
CE/IVD:
RUO
Extra Details:
Tau dGAE (297-391) represents a truncated segment of the microtubule-associated protein tau, encompassing the core region responsible for pathological aggregation. This fragment includes the repeat domains critical for B Beta-sheet formation and fibrillization, making it a minimal yet potent model for studying tau-driven neurodegeneration. When assembled into pre-formed fibrils (PFFs), Tau dGAE adopts structural features that closely mimic those found in Alzheimer's disease (AD) brain-derived tau aggregates. These AD-mimic PFFs exhibit high seeding efficiency, inducing endogenous tau misfolding and aggregation in cellular and animal models. Their ability to replicate key aspects of tau pathology-including filament morphology, phosphorylation patterns, and neurotoxicity-makes them a powerful tool for mechanistic studies. Tau dGAE AD-mimic PFFs enable researchers to investigate the prion-like propagation of tau aggregates, synaptic dysfunction, and neuronal loss. Their reproducibility and disease relevance support high-throughput screening of anti-tau therapeutics, including aggregation inhibitors, immunotherapies, and modulators of tau clearance pathways. By modeling the structural and functional hallmarks of tau pathology, Tau dGAE AD-mimic PFFs accelerate translational research aimed at halting tau-mediated neurodegeneration. Their use bridges the gap between in vitro biophysics and in vivo disease modeling, offering a robust platform for therapeutic development in Alzheimer's disease and related tauopathies. Advances in Cryo-EM have revealed that tau filaments isolated from individuals with a particular neurodegenerative disease share a distinct tau fold - i.e. an AD-isolated Tau filaments' fold is distinct from a CTE-isolated Tau filaments' fold (1-3). Utilizing Tau filaments with the correct disease-specific fold is an important goal towards better mimicking specific human diseases in cellular and in vivo models. Recent Cryo-EM studies have demonstrated that recombinantly generated Tau dGAE monomers will form the disease-isolated AD or CTE Tau filament folds under highly specific conditions in vitro (4, 5). StressMarq's Tau dGAE (297-391) AD-mimic PFFs are purified and fibrilized under these exact published conditions that replicate the disease-isolated AD-fold (200 rpm at 37oC in 10 mM PB 10 mM DTT pH 7.4 200 mM MgCl2 for 48 hours).
Immunogen:
Tau dGAE (297-391) AD-mimic PFFs
Molecular Weight:
10.165 kDa
Purity:
>95%
Purification:
Ion Exchange
Sequence:
MIKHVPGGGSVQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPGGGNKKIETHKLTFRENAKAKTDHGAE
Shipping Conditions:
Dry Ice
Storage Conditions:
-70[o]C
Supplier:
StressMarq Biosciences
Type:
Proteins, Peptides, Small Molecules & Other Biomolecules: Recombinant Proteins